Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Edward Garon, M.D., M.S.
Edward Garon, M.D., M.S.

Specialty:

Hematology/Oncology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Associate Clinical Professor, Department of Medicine, Hematology/Oncology
Director, Thoracic Oncology Program
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Santa Monica - UCLA Medical Center and Orthopaedic Hospital
Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Hematology/Oncology, UCLA School of Medicine, 2003 - 2006
Residency:
Internal Medicine, University of Chicago Hospitals, 2000 - 2002
Internship:
Internal Medicine, University of Chicago Hospitals, 1999 - 2000
Medical Degree:
M.D., Washington University School of Medicine, 1999

Certification(s):

Board Certification(s):
Hematology and Oncology, American Board of Internal Medicine, 2006
Medical Oncology, American Board of Internal Medicine, 2006
Internal Medicine, American Board of Internal Medicine, 2002

Contact Information:

Phone:
(310) 586-2098 Office
(310) 829-5471 Patient referrals
Email:

Practice Information:

Clinical Interest(s):
Thoracic

Scientific Interest(s):

Dr. Edward Garon's research focuses on developing novel therapies for cancers of the chest (most frequently lung cancer). In his laboratory work, he focuses on determining molecular subtypes of these common cancers. He then evaluates the effects of novel therapeutics against these different subtypes.

In addition to laboratory research, Garon is the principal investigator on a wide range of clinical trials. The ultimate goal of his work is to determine subgroups of lung cancer patients most likely to respond to certain therapies and then translate those observations into rational clinical trials. These trials look at both therapies targeting specific abnormalities in the tumor, as well as therapies that induce the immune system to attack the tumor.

Selected Cancer-Related Publications:

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2.

Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741.

Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, Jensen MR, Quadt C, Liu M, Dubinett SM, Slamon DJ. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther. 2013 Jun;12(6):890-900. doi: 10.1158/1535-7163.MCT-12-0998. Epub 2013 Mar 14.

Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Márquez-Garbán DC, Desai AJ, Dering J, Hosmer W, von Euw EM, Dubinett SM, Slamon DJ. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol. 2013 Mar;8(3):270-8. doi: 10.1097/JTO.0b013e31827d525c.

Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther. 2010 Jul;9(7):1985-94. Epub 2010 Jun 29.